A Phase 2 interventional study of RE104 for Injection in Adjustment Disorder, sponsored by Reunion Neuroscience Inc. Recruiting at 33 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Reunion Neuroscience Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Adjustment Disorders with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Adjustment Disorders · United States.
Among the 15 studies in Adjustment Disorders with a site in United States, this one is the 3rd largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is one of 4 in phase 2, and was the 14th registered.
63 studies on the registry are indexed under Adjustment Disorders; 13 are open to participants now.
Browse Adjustment Disorders studies →6 of the 15 studies in Adjustment Disorders with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–90
Henry M. Jackson Foundation for the Advancement of Military Medicine · Sites in United States
Ages 18–64
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+
Sunstone Medical · Sites in United States
Ages 18+
Nautilus Sanctuary · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Adjustment Disorders studies recruiting now, 4 (36%) set no upper age limit and 3 (27%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 1
First in 1999; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 52 interventional studies indexed under Adjustment Disorders.
Median enrollment 41 across the 13 interventional studies, 433 across the 2 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 15 have an industry lead sponsor. The 10 most frequent:
Reunion Neuroscience Inc is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Reunion Neuroscience Inc has 1 study filed under Adjustment Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Adjustment Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07002034Reunion Neuroscience IncRE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | 2027-04 |
| NCT07221409Mayo ClinicVirtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients Undergoing Treatment | 2027-10-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Adjustment Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
The criteria were revised on the registry on Nov 10, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single subcutaneous injection of 1.5 mg RE104 for Injection
Drug: RE104 for Injection
A single subcutaneous injection of 30 mg RE104 for Injection
Drug: RE104 for Injection
Single, subcutaneous dose of RE104 for Injection
RE104 30 mg versus RE104 1.5 mg change from baseline in MADRS total score
Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity. The total score ranges from 0-60 with higher scores representing greater severity of depression.
Time frame: Day 7
RE104 30 mg versus RE104 1.5 mg changes in total score from baseline in Hamilton Anxiety Rating Scale (HAM-A)
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety.
Time frame: Day 7
RE104 30 mg versus RE104 1.5 mg incidence of treatment-emergent adverse events (TEAEs) by frequency, severity and seriousness.
A treatment-emergent adverse event (TEAE) is defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a study drug.
Time frame: From dosing through study completion (post-dose follow-up is for 42 days)
Not enrolling at this site — choose another above.
Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Apr 2027, 21 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Nov 2026 → Apr 2027 and completion Dec 2026 → May 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Luvesilocin
Reunion Neuroscience Inc